Return to search results.
Complete title: HLA-Haploidentical Related Marrow Grafts for the Treatment of Immunodeficiency and Other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, 200 cGy TBI and Fludarabine; Postgrafting Immunosuppression Will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus.
|Research Study Number||2032.00|
|Principal Investigator||Lauri Burroughs, MD|
Research Study Description
Most of the treatment will be given at the Seattle Cancer Care Alliance (SCCA) outpatient clinic. Initial in-hospital treatment will be given at the University of Washington Medical Center or Childrens Hospital and Regional Medical Center.
Participants will be in the study for at least one year, and will come to the SCCA clinic for treatment for about four months (about one month before the transplant and three months after the transplant).
Additional bone marrow or blood samples may be drawn at various time points for up to five years after the transplant.
Eligibility Criteria (must meet the following to participate in this study)
Non-malignant disease treatable by allogeneic stem cell transplantation.
Patient is at high risk of having toxic side effects, or is ineligible for a conventional myeloablative stem cell transplantation,
Patient does not have a genetically matched (HLA-matched, related or unrelated) donor.
Other eligibility criteria may apply.
Exclusions (conditions that would prevent participation in this study)
Patients with HLA-matched (genetically matched) related or unrelated donors
Patients with HIV
Patients who are female and are pregnant or breastfeeding
Other exclusion criteria may apply.
Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Immunodeficiency Syndromes; Severe Combined Immunodeficiency Syndrome (SCID); Non-malignant Condition
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.